Indiana University Melvin and Bren Simon Comprehensive Cancer Center Joins Caris Precision Oncology Alliance
IU Simon Comprehensive Cancer Center joins Caris' network of cancer institutions committed to utilizing clinical data to advance patient care and outcomes.
Caris Life Sciences announced that Indiana University Melvin and Bren Simon Comprehensive Cancer Center has joined the Caris Precision Oncology Alliance™ (POA). The POA is a growing network of cancer centers that collaborate to advance oncology and biomarker research.
Established in 1992, the IU Simon Comprehensive Cancer Center is Indiana's sole National Cancer Institute (NCI)-designated comprehensive cancer center. It conducts all phases of cancer research, from laboratory studies to clinical trials to population-based studies.
Read more about the POA
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Articles
How the NIMBLE Study Supported Adherence With Quarterly Dosing of CemdisiranSeptember 18th 2025
Everything to Know About FDA’s Push Towards Radical Transparency in 2025September 17th 2025
IQVIA and Veeva Join Forces to Improve Efficiency and Patient OutcomesSeptember 17th 2025
Managing Background Therapies in the NIMBLE Phase III TrialSeptember 17th 2025
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
